Follows adults with psoriatic arthritis treated with risankizumab over time
Observes how long adults with psoriatic arthritis stay on risankizumab compared with other treatments.
Plain-language title generated from the registry record
Registry title: An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Key facts
- Where
- Ancona, Brescia, Campobasso, Catania, Chieti, Milan, Naples, Pisa, Rome, Rozzano, Siena, and Udine, ItalySee the 13 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06764693, who can take part
Where in Italy
- Azienda Ospedaliero Universitaria delle Marche /ID# 264636Ancona, ItalyTaking people
- ASST degli Spedali Civili di Brescia /ID# 264699Brescia, ItalyTaking people
- Universita degli Studi del Molise /ID# 265162Campobasso, ItalyTaking people
- AOU Policlinico G. Rodolico - San Marco /ID# 264459Catania, ItalyTaking people
- ASL 2 Abruzzo Lanciano-Vasto-Chieti /ID# 265640Chieti, ItalyTaking people
- ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 265161Milan, ItalyTaking people
- IRCCS Ospedale San Raffaele /ID# 266212Milan, ItalyTaking people
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 266888Naples, ItalyTaking people
- Azienda Ospedaliero Universitaria Pisana /ID# 264938Pisa, ItalyTaking people
- Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 265145Rome, ItalyTaking people
- IRCCS Istituto Clinico Humanitas /ID# 264463Rozzano, ItalyTaking people
- Azienda Ospedaliera Universitaria Senese /ID# 265207Siena, ItalyTaking people
- ASU FC - P.O. Universitario Santa Maria della Misericordia /ID# 264698Udine, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06764693
- Record updated
- 17 February 2026
- Original description
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.Read full original descriptionShow less
Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice.
Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents.
The therapy is prescribed in the usual manner in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population, and indication. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
There is expected to be no additional burden for participants in this study.
Inclusion: Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease; Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.
Exclusion: Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).